GenSci Expects Topical Molgramostim Gel Approval in 2007.SHANGHAI, China -- GeneScience Pharmaceuticals Co., Ltd. (GenSci) announced today that the company's new drug, Genfulin[TM], a topical gel indicated for the treatment of wound healing wound healing Physiology The repair of a wound Steps Inflammation, repair and closure, remodeling, final healing; repair of incisions may be either simple–'clean' wounds with little loss of tissue heal by 'primary intention', or 'dirty' wounds heal by , is expected to get approval by China's SFDA SFDA State Food and Drug Administration (China) SFDA Saudi Food & Drug Authority in early 2007. The active ingredient in Genfulin[TM] is molgramostim (human granulocyte-macrophage colony stimulating factor colony stimulating factor n. A hormone produced in the cells lining the blood vessels that stimulates the bone marrow to synthesize white blood cells. , hGM-CSF (rDNA origin). GenSci has been the top biopharmaceutical manufacturer for Jintropin(TM) somatropin (human growth hormone human growth hormone (HGH): see growth hormone. , hGH), Scimax(TM) filgrastim (human granulocyte granulocyte /gran·u·lo·cyte/ (gran´u-lo-sit?) granular leukocyte.granulocyt´ic band-form granulocyte band cell. gran·u·lo·cyte n. colony stimulating factor, G-CSF G-CSF granulocyte colony-stimulating factor. G-CSF granulocyte-colony stimulating factor. G-CSF Granulocyte colony-stimulating factor Molecular therapeutics A biological response modifier, the recombinant DNA form of ) and molgramostim in China. "With the unique innovative formulation, Genfulin[TM] marks the major step in GenSci's transition to manufacturing biological supergenerics," according to Dr. Lei Jin, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of GenSci. Based on the current indications of molgramostim, Genfulin[TM] gel was designed for new indications in wound healing with its novel and unique formulation. Most importantly, clinical trials of Genfulin[TM] have confirmed its efficacy in actively accelerating wound healing, increasing wound tearing-resistance, and reducing, even avoiding, scar proliferation in burn patients. Similar effects have also been observed in chronic ulcer patients, including those with diabetic foot ulcer. Overall, Genfulin[TM] gel has been shown to improve the quality of wound healing significantly with a good safety profile, according to results obtained from clinical trials. Genfulin[TM] gel is applied to wound areas directly in patients with burn, scald or ulcer to speed up the healing. GenSci holds a patent for Genfulin[TM], which was developed with GenSci's proprietary technology platform by scientists at GenSci. Genfulin, Jintropin, Scimax are trademarks of GenSci. About GenSci GenSci (www.gensci-china.com) is the leading Chinese biopharmaceutical company that develops, manufactures and markets biological therapeutics focused on endocrinology and related areas, aiming at providing affordable and innovative biopharmaceutical products to patients. The company is privately-held and headquartered in Changchun, China. Products include: Jintropinsomatropin (rhGH for injection), Jintropin AQ somatropin liquid pen, Scimax filgrastim (rhG-CSF injection), Granmac molgramostim (rhGM-CSF for injection), Jintrotide (octreotide acetate for injection) and Jintrirelin (triptorelin acetate injection). For more information, visit www.gensci-china.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion